Mofecon-S 360 characteristics
|Therapeutic classification||Selective immunosuppressant|
|Dosage form||360 mg|
| Dosage strength||tablet|
|Produced by||Concord Biotech / India|
|Indication||prevent organ rejection in patients who are at least three months of age who have received a liver transplant, a heart transplant, or a kidney transplant.|
|Mechanism of action||Mycophenolate is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-5′-monophosphate dehydrogenase. MPA depletes guanosine nucleotides preferentially in T and B lymphocytes and inhibits their proliferation, thereby suppressing cell-mediated immune responses and antibody formation.|
|Use in pregnancy and breastfeeding||D in pregnancy|
Information on the use of mycophenolate while breastfeeding is very limited. Be sure talk to your healthcare provider about all of your breastfeeding questions.
|Precautions||The most common side effects of taking MOFECON S-360 TABLET are nausea, vomiting, diarrhea, stomach pain, headache, high blood pressure, and low number of white blood cells.|
|Drug interactions||other drugs that weaken the immune system/increase the risk of infection (such as natalizumab, rituximab).|
Mycophenolate may decrease the excretion rate of Abacavir, could result in a higher serum level.
|Superior features ||FDA approved|